Correlated expression of high-sensitivity C-reactive protein in relation to disease activity in inflammatory bowel disease: Lack of differences between Crohn's disease and ulcerative colitis

Digestion

Volumn 73, Issue 4, 2006, Pages 205-209

  Zilberman, Liaz ^a   Maharshak, Nitsan ^a   Arbel, Yaron ^a   Rogowski, Ori ^a   Rozenblat, Meirav ^a   Shapira, Itzhak ^a   Berliner, Shlomo ^a   Arber, Nadir ^a,b   Dotan, Iris ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

C reactive protein; Crohn's disease; High sensitivity; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; HIGH SENSITIVITY C REACTIVE PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE ACTIVITY; ENTERITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAYO SCORE; NEPHELOMETRY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SCORING SYSTEM; ULCERATIVE COLITIS;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; CROHN DISEASE; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NEPHELOMETRY AND TURBIDIMETRY; SEVERITY OF ILLNESS INDEX;

EID: 33748993699     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094531     Document Type: Article

References (20)

1. Vermeire S, Van AG, Rutgeerts P: Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006;55:426-431.
2. Pepys MB, Hirschfield GM: C-reactive protein: a critical update. J Clin Invest 2003;111:1805-1812.
3. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S: Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32.
4. Gordon FH, Hamilton MI, Donoghue S, Greenlees C, Palmer T, Rowley-Jones D, Dhillon AP, Amlot PL, Pounder RE: A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002;16:699-705.
5. Conroy CA, Cattell R: Infliximab treatment for Crohn's disease. Postgrad Med J 2001;77:436-440.
6. Best WR, Becktel JM, Singleton JW: Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979;77:843-846.
7. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-2476.
8. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, Dube R, Cohen A, Steinhart AH, Landau S, Aguzzi RA, Fox IH, Vandervoort MK: Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352:2499-2507.
9. Schroeder KW, Tremaine WJ, Ilstrup DM: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-1629.
10. Rogowski O, Toker S, Shapira I, Melamed S, Shirom A, Zeltser D, Berliner S: Values of high sensitivity C-reactive protein in each month of the year in apparently healthy individuals. Am J Cardiol 2005;95:152-155.
11. Berliner S, Rogowski O, Aharonov S, Mardi T, Tolshinsky T, Rozenblat M, Justo D, Deutch V, Serov J, Shapira I, Zeltser D: Erythrocyte adhesiveness/aggregation. A novel biomarker for the detection of low grade internal inflammation in individuals with atherothrombotic risk factors and proven. Vascular disease. Am Heart J 2005;149:260-267.
12. Rogowski O, Vered Y, Shapira I, Hirsh M, Zakut V, Berliner S: Introducing the wide range C-reactive protein (wr-CRP) into clinical use for the detection of microinflammation. Clin Chim Acta 2005;358:151-158.
13. Clauss A: Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol Basel 1957;17:237-246.
14. International Committee for Standardization in Hematology: Recommendation of measurement of erythrocyte sedimentation rate of human blood. Immunochemistry 1965;2:235-254.
15. Rifai N, Tracy RP, Ridker PM: Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999;45:2136-2141.
16. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;11:448-454.
17. Vatay A, Bene L, Kovacs A, Prohaszka Z, Szalai C, Romics L, Fekete B, Karadi I, Fust G: Relationship between the tumor necrosis factor alpha polymorphism and the serum C-reactive protein levels in inflammatory bowel disease. Immunogenetics 2003;55:247-252.
18. Bene L, Fust G, Fekete B, Kovacs A, Horvath L, Prohaszka Z, Miklos K, Palos G, Daha M, Farkas H, Varga L: High normal serum levels of C3 and C1 inhibitor, two acute-phase proteins belonging to the complement system, occur more frequently in patients with Crohn's disease than ulcerative colitis. Dig Dis Sci 2003;48:1186-1192.
19. Sachar DB, Smith H, Chan S, Cohen LB, Lichtiger S, Messer J: Erythrocytic sedimentation rate as a measure of clinical activity in inflammatory bowel disease. J Clin Gastroenterol 1986;8:647-650.
20. Sachar DB, Luppescu NE, Bodian C, Shlien RD, Fabry TL, Gumaste VV: Erythrocyte sedimentation as a measure of Crohn's disease activity: opposite trends in ileitis versus colitis. J Clin Gastroenterol 1990;12:643-646.